Isolated limb perfusion for malignant melanoma

Seminars in Surgical Oncology

Volumn 12, Issue 6, 1996, Pages 416-428

  Alexander Jr , H Richard ^a   Fraker, Douglas L ^b   Bartlett, David L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

hyperthermia; in transit melanoma; melphalan; regional perfusion; tumor necrosis factor

Indexed keywords

ALKYLATING AGENT; CISPLATIN; DACARBAZINE; DACTINOMYCIN; GAMMA INTERFERON; INTERLEUKIN 2; MELPHALAN; THIOTEPA; TUMOR NECROSIS FACTOR ALPHA;

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; HYPERTHERMIC THERAPY; LIMB PERFUSION; MELANOMA; PRIORITY JOURNAL; REGIONAL PERFUSION; REVIEW;

ANTINEOPLASTIC AGENTS, ALKYLATING; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTHERMIA, INDUCED; INTERFERON TYPE II; LEG; MELANOMA; MELPHALAN; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 10344246059     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(199611/12)12:6<416::AID-SSU7>3.0.CO;2-D     Document Type: Review

References (85)

1. Balch CM, Soong SJ, Shin HM, et al: Changing trends in the clinical and pathologic features of melanoma. In Balch CM, Houghton AN, Milton GW, et al (eds): "Cutaneous Melanoma." Philadelphia: Lippincott, 1992, 40-45.
2. Coit DG: Hyperthermic isolation limb perfusion for malignant melanoma: a review. Cancer Invest 10:277-284, 1992.
3. Turnbull A, Shah J, fortner J: Recurrent melanoma of an extremity treated by major amputation. Arch Surg 106:496-498, 1973.
4. Jaques DP, Coit DG, Brennan MF: Major amputation for advanced malignant melanoma. Surg Gynecol Obstet 169:1-6, 1989.
5. Klaase JM, Kroon BB, van Geel AN, et al: Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion using melphalan. Surgery 115:39-45, 1994.
6. Creech O, Krementz ET, Ryan RF, et al: Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 148: 616-632, 1958.
7. Cavaliere R, Ciogatto EC, Giovanelli BC, et al: Selective heat sensitivity of cancer cells. Cancer 20:1351-1387, 1967.
8. Hahn GM, Strande DP: Cytotoxic effects of hyperthermia and adriamycin on Chinese hamster cells. J Natl Cancer Inst 57:1063-1067, 1976.
9. Zaffaroni N, Villa R, Orlandi L, et al: Effect of hyperthermia on the formation and removal of DNA interstrand cross-links induced by melphalan in primary cultures of human malignant melanoma. Int J Hyperthermia 8:341-349, 1992.
10. Stehlin JS: Hyperthermic perfusion with chemotherapy for cancers of the extremities. Surg Gynecol Obstet 129:305-308, 1969.
11. Karakousis CP, Choe KJ, Holyoke ED: Biologic behavior and treatment of intransit metastasis of melanoma. Surg Gynecol Obstet 150:29-32, 1980.
12. Morton DL, Eilber FR, Holmes EC, et al: BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg 180:635-643, 1974.
13. Bowers GJ, Copeland EM: Surgical limb perfusion for extremity melanoma. Surg Oncol 3:91-102, 1994.
14. Coil DG: Isolation limb perfusion for melanoma: current trends and future directions. Melanoma Res 4:57-60, 1994.
15. Klaase JM, Kroon BB, van Geel AN, et al: The role of regional isolated perfusion in the eradication of melanoma micrometastases in the inguinal nodes: a comparison between an iliac and femoral perfusion procedure. Melanoma Res 2:407-410, 1992.
16. Klaase JM, Kroon BB, van Geel AN, et al: Systemic leakage during isolated limb perfusion for melanoma. Br J Surg 80:1124-1126, 1993.
17. Klaase JM, Kroon BB, van Slooten GW, et al: Comparison between the use of whole blood versus a diluted perfusate in regional isolated perfusion by continuous monitoring of transcutaneous oxygen tension: a pilot study. J Invest Surg 7:249-258, 1994.
18. Thom AK, Alexander HR, Andrich MP, et al: Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion (ILP) with high-dose TNF, interferon-gamma and melphalan. J Clin Oncol 13:264-273, 1995.
19. Barker WC, Andrich MP, Alexander HR, et al: Continuous intraoperative external monitoring of perfusate leak using I-131 human serum albumin during isolated perfusion of the liver and limbs. Eur J Nucl Med 22:1242-1248, 1995.
20. Hoekstra HJ, Naujocks T, Schraffordt-Koops H, et al: Continuous leaking monitoring during hyperthermic isolated regional perfusion of the lower limb: techniques and results. Reg. Cancer Treat 4:301-304, 1992.
21. Luck JM: Action of p-dichloroethyl amino-L-phenylalanine on Harding-Passey mouse melanoma. Science 123:984-985, 1956.
22. Wieberdink J, Benckhuysen C, Braat RP, et al: Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 18:905-910, 1982.
23. Scott RN, Kerr DJ, Blackie R, et al: The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma. Br J Cancer 68:159-166, 1992.
24. Scott RN, Blackie R, Kerr DJ, et al: Melphalan concentration and distribution in the tissues of tumour-bearing limbs treated by isolated limb perfusion. Eur J Cancer 28:1811-1813, 1992.
25. Klaase JM, Kroon BB, Beijnen JH, et al: Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb. Br J Cancer 70:151-153, 1994.
26. di Filippo F, Calabrö A, Giannarelli D, et al: Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer 63:2551-2561, 1989.
27. van de Merwe SA, van den Berg AP, Kroon BB, et al: Modification of human tumour and normal tissue pH during hyperthermic and normothermic antiblastic regional isolation perfusion for malignant melanoma: a pilot study. Int J Hyperthermia 9:205-217, 1996.
28. Klaase JM, Kroon BB, van Geel AN, et al: Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion. J Am Coll Surg 178:564-572, 1994.
29. Olieman AF, Koops HS, Geertzen JH, et al: Functional morbidity of hyperthermic isolated regional perfusion of the extremities. Ann Surg Oncol 1:382-388, 1994.
30. Klaase JM, Kroon BB, van Geel BN, et al: Patient- and treatment-related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities. Am J Surg 167:618-620, 1994.
31. Skene AI, Bulman AS, Williams TR, et al: Hyperthermic isolated perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limb. Br J Surg 77:765-767, 1990.
32. Vrouenraets BC, Eggermont AM, Klaase JM, et al: Long-term neuropathy after regional isolated perfusion with melphalan for melanoma of the limbs. Eur J Surg Oncol 20:681-685, 1994.
33. Jonsson PE, Haistrom L, Hugander A: Results of regional hyperthermic perfusion for primary and recurrent melanomas of the extremities. Recent Results Cancer Res 86:277-282, 1983.
34. Sugarbaker EV, McBride CM: Survival and regional disease control after isolation-perfusion for invasive stage I melanoma of the extremities. Cancer 37:188-198, 1976.
35. Janoff KA, Moseson D, Nohlgren J, et al: The treatment of stage I melanoma of the extremities with regional hyperthermic isolation perfusion. Ann Surg 196:316-323, 1982.
36. Rege VB, Leone LA, Soderberg CH Jr, et al: Hyperthermic adjuvant perfusion chemotherapy for stage I malignant melanoma of the extremity with literature review. Cancer 52:2033-2039, 1983.
37. Martijn H, Koops HS, Milton GW, et al: Comparison of two methods of treating primary malignant melanomas Clark IV and V, thickness 1.5 mm and greater, localized on the extremities. Cancer 57: 1923-1930, 1986.
38. Franklin HR, Koops HS, Oldhoff J, et al: To perfuse or not to perfuse? A retrospective comparative study to evaluate the effect of adjuvant isolated regional perfusion in patients with stage I extremity melanoma with a thickness of 1.5 mm or greater. J Clin Oncol 6:701-708, 1988.
39. Reintgen DS, Cruse CW, Wells KE, et al: Isolated limb perfusion for recurrent melanoma of the extremity. Ann Plast Surg 28:50-54, 1992.
40. Vrouenraets BC, Kroon BB, Klaase JM, et al: Adjuvant regional isolated perfusion with melphalan for patients with Clark V melanoma of the extremities. J Surg Oncol 52:249-254, 1993.
41. Vrouenraets BC, Kroon BB, Klaase JM, et al: Regional isolated perfusion with melphalan for patients with subungual melanoma. Eur J Surg Oncol 19:37-42, 1993.
42. Edwards MJ, Soong SJ, Boddie AW, et al: Isolated limb perfusion for localized melanoma of the extremity. Arch Surg 125:317-321, 1990.
43. Koops HS, Kroon BB, Oldhoff J, et al: Controversies concerning adjuvant regional isolated perfusion for stage I melanoma of the extremities. World J Surg 16:241-245, 1992.
44. Sutherland CM, Mather FJ, Krementz ET: Factors influencing the survival of patients with regional melanoma of the extremity treated by perfusion. Surg Gynecol Obstet 164:111-118, 1987.
45. Ghussen F, Nagel K, Groth W, et al: A prospective randomized study of regional extremity perfusion in patients with malignant melanoma. Ann Surg 200:764-768, 1984.
46. Ghussen F, Kruger I, Groth W, et al: The role of regional hyperthermic cytostatic perfusion in the treatment of extremity melanoma. Cancer 61:654-659, 1988.
47. Hafstrom L, Rudenstam CM, Blomquist E, et al: Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. J Clin Oncol 9:2091-2094, 1991.
48. Lejeune FJ: A randomized trial on prophylactic isolation perfusion for stage I high risk (i.e., 1.5 mm thickness) malignant melanoma of the limbs: an interim report [abstr]. (Third International Conference on Melanoma; 1993 Mar 31-Apr 3; Venice, Italy.) Melanoma Res 3 (suppl 1):95, 1993.
49. Bulman AS, Jamieson CW: Isolated limb perfusion with melphalan in the treatment of malignant melanoma. Br J Surg 67:660-662, 1980.
50. Kroon BB, van Geel, AN, Benckhuijsen C, Wieberdink J: Normothermic isolation perfusion with melphalan for advanced melanoma of the limbs. Anticancer Res 7 (3 Pt B):441-442, 1987.
51. Lejeune FJ, Deloof T, Ewalenko P, et al: Objective regression of unexcised melanoma in-transit metastases after hyperthermic isolation perfusion of the limbs with melphalan. Recent Results Cancer Res 86:268-276, 1983.
52. Kapteijn BA, Klaase JM, van Geel AN, et al: Results of regional isolated perfusion for locally inoperable melanoma of the limbs. Melanoma Res 4:135-138, 1994.
53. Minor DR, Allen RE, Alberts D, et al: A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma. Cancer 55:2638-2644, 1985.
54. Hafström L, Jonsson PE: Hyperthermic perfusion of recurrent malignant melanoma on the extremities. Acta Chir Scand 146:313-318, 1980.
55. Klaase JM, Kroon BB, van Geel AN, et al: A retrospective comparative study evaluating the results of a single-perfusion versus double-perfusion schedule with melphalan in patients with recurrent melanoma of the lower limb. Cancer 71:2990-2994, 1993.
56. Guchelaar HJ, Hoekstra HJ, de Vnes EG, et al: Cisplatin and platinum pharmacokinetics during hyperthermic isolated limb perfusion for human tumors of the extremities. Br J Cancer 65:898-902, 1992.
57. Reicher WS, Woltering EA, Moseley HS, et al: Hyperthermic isolation limb perfusion (HILP) in the management of extremity melanoma and sarcoma with particular reference to the dosage, pharmacokinetics. and toxicity of cisplatin. In Humphrey GB (ed): "Osteosarcoma in Adolescents and Young Adults." Boston: Kluwer Academic, 1993, 241-244.
58. Omlor G, Gross G, Ecker KW, et al: Optimization of isolated hyperthermic limb perfusion. World J Surg 16:1117-1119, 1992.
59. Hoekstra HJ, Koops HS, de Vries LG, et al: Toxicity of hyperthermic isolated limb perfusion with cisplatin for recurrent melanoma of the lower extremity after previous perfusion. Cancer 72:1224-1229, 1993.
60. Fletcher WS, Pommier R, Small K: Results of cisplatin hyperthermic isolation perfusion for stage IIIA and IIIAB extremity melanoma. Melanoma Res 4:17-19, 1994.
61. Roseman JM: Effective management of extremity cancers using cisplatin and etoposide in isolated limb perfusions. J Surg Oncol 35:170-172, 1987.
62. Martijn H, Oldhoff J, Koops HS: Hyperthermic regional perfusion with melphalan and a combination of melphalan and actonomycin D in the treatment of locally metastasized malignant melanomas of the extremities. J Surg Oncol 20:9-13, 1982.
63. Didolkar MS, Fitzpatrick JL, Jackson AJ, et al: Toxicity and complications of vascular isolation and hyperthermic perfusion with imidazole carboxamide (DTIC) in melanoma. Cancer 57:1961-1966, 1986.
64. Cavaliere R, Cavaliere F, Deeraco M, et al: Hyperthermic antiblastic perfusion in the treatment of stage IIIA-IIIB melanoma patients. Comparison of two experiences. Melanoma Res 4:5-11, 1994.
65. Belli F, Arienti F, Rivoltini L, et al: Treatment of recurrent intransit metastases from cutaneous melanoma by isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine activated killer cells. A pilot study. Melanoma Res 2:263-271, 1992.
66. Thompson JF, Gianoutsos MP: Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 16:227-233, 1992.
67. Coit DG: Hyperthermic isolation limb perfusion (HILP) with cisplatin (CDDP) for metastatic intransit melanoma: a phase I-II trial [abstr]. (Third International Conference on Melanoma; 1993 Mar 31-Apr 3; Venice, Italy.) Melanoma Res 3 (suppl 1):98, 1993.
68. Lienard D, Ewalenko P, Delmotti JJ, et al: High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10:52-60, 1992.
69. Lienard D, Lejeune F, Ewalenko I: In-transit metastases of malignant melanoma treated by high dose rTNFa in combination with interferon-gamma and melphalan in isolation perfusion. World J Surg 16:234-240, 1992.
70. Carswell EA, Old LJ, Kassel RL, et al: An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72:3666-3670, 1975.
71. Cumberlin R, De Moss E, Lassus M, Friedman M: Isolation perfusion for malignant melanoma of the extremity: a review. J Clin Oncol 3:1022-1031, 1985.
72. Posner MC, Lienard D, Lejeune FJ, et al: Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma. Cancer J Sci Am 1:274-280, 1995.
73. Lejeune FJ: High dose recombinant tumour necrosis factor (rTNFa) administered by isolation perfusion for advanced tumours of the limbs: a model for biochemotherapy of cancer. Eur J Cancer 31A:1009-1016, 1995.
74. Aggarwal BB, Eessalu TE, Hass PE: Characterization of receptors for tumor necrosis factor and their regulation by gamma-interferon. Nature 318:665-667, 1985.
75. Balkwill FR, Lee A, Aldant G, et al: Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons. Cancer Res 46:3990-3993, 1986.
76. Liénard D, Eggermont A, Koops HS, et al: The use of TNF in isolated limb perfusion for treatment of locally advanced melanoma: an update [abstr]. (Cambridge Symposia: TNF and related cytokines: clinical utility and biology of action; 1996 Mar 10-16: Hilton Head, SC.) Cambridge Symposia 1:12, 1996.
77. th Annual Cancer Symposium of the Society of Surgical Oncology: Society of Surgical Oncology Abstract Book 49:6, 1996.
78. Fraker DL, Alexander HR: The use of tumour necrosis factor (TNF) in isolated perfusion: results and side effects. The NCI results. Melanoma Res 4:27-29, 1994.
79. Fraker DL, Alexander HR, Andrich M, et al: Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor. Cancer J Sci Am 1:122-130, 1995.
80. rd Annual Meeting of the American Society of Clinical Oncology: 1996 May 16-18: Philadelphia, PA 15:53, 1996.
81. Hill S, Fawcett WJ, Sheldon J, et al: Low-dose tumour necrosis factor a and melphalan in hyperthermic isolated limb perfusion. Br J Surg 80:995-997, 1993.
82. Vaglini M, Belli F, Ammaruna M, et al: Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose alpha-tumor necrosis factor, gamma-interferon, and melphalan. Cancer 73:483-492, 1994.
83. Fawcett WJ, Hill S, Sheldon J, et al: Hemodynamic changes and circulating recombinant tumor necrosis factor-a concentrations in a patient undergoing isolated limb perfusion. Crit Care Med 21:796, 1993.
84. Ghussen F, Nagel K, Groth W, et al: A prospective randomized study of regional extremity perfusion in patients with malignant melanoma. Ann Surg 200:764-768, 1984.
85. Fraker DL, Alexander HR: The use of tumor necrosis factor in isolated limb perfusions for melanoma and sarcoma. PPO Updates 7:1-10, 1993.